MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. (nature.com)

Authors: Wermke M … Reinhardt C Journal: Nature Medicine Published: 2026-05-31 DOI: https://doi.org/10.1038/s41591-026-04455-x